Reuters logo
BRIEF-Neovacs obtains FDA "Fast Track" designation for IFNalpha Kinoid in Lupus (SLE)
December 7, 2016 / 6:18 AM / a year ago

BRIEF-Neovacs obtains FDA "Fast Track" designation for IFNalpha Kinoid in Lupus (SLE)

Dec 7 (Reuters) - Neovacs SA :

* Neovacs is currently enrolling patients in an international phase IIb trial (IFN-K 002) in Lupus (SLE)

* This study, which has already recruited more than half of its targeted 178 patients, is underway in 21 countries in Europe, Asia, Latin America and US Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below